JP2009544721A - プロスタグランジンd2受容体アンタゴニストとしての2−フェニルインドール類 - Google Patents

プロスタグランジンd2受容体アンタゴニストとしての2−フェニルインドール類 Download PDF

Info

Publication number
JP2009544721A
JP2009544721A JP2009521914A JP2009521914A JP2009544721A JP 2009544721 A JP2009544721 A JP 2009544721A JP 2009521914 A JP2009521914 A JP 2009521914A JP 2009521914 A JP2009521914 A JP 2009521914A JP 2009544721 A JP2009544721 A JP 2009544721A
Authority
JP
Japan
Prior art keywords
chloro
phenyl
indol
pharmaceutically acceptable
acetic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2009521914A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544721A5 (cg-RX-API-DMAC7.html
Inventor
チャウシア・ヤン
シュテファン・ライリング
サディーアス・アール・ニードゥザク
ローズ・エム・マシュー
シャロン・ジャクソン
キース・ジェイ・ハリス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of JP2009544721A publication Critical patent/JP2009544721A/ja
Publication of JP2009544721A5 publication Critical patent/JP2009544721A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
JP2009521914A 2006-07-25 2007-07-20 プロスタグランジンd2受容体アンタゴニストとしての2−フェニルインドール類 Abandoned JP2009544721A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82029906P 2006-07-25 2006-07-25
US82030106P 2006-07-25 2006-07-25
US82030206P 2006-07-25 2006-07-25
PCT/US2007/073945 WO2008014186A1 (en) 2006-07-25 2007-07-20 2-phenyl-indoles as prostaglandin d2 receptor antagonists

Publications (2)

Publication Number Publication Date
JP2009544721A true JP2009544721A (ja) 2009-12-17
JP2009544721A5 JP2009544721A5 (cg-RX-API-DMAC7.html) 2010-09-02

Family

ID=38610820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521914A Abandoned JP2009544721A (ja) 2006-07-25 2007-07-20 プロスタグランジンd2受容体アンタゴニストとしての2−フェニルインドール類

Country Status (25)

Country Link
US (1) US20090176804A1 (cg-RX-API-DMAC7.html)
EP (1) EP2066628B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009544721A (cg-RX-API-DMAC7.html)
KR (1) KR20090039735A (cg-RX-API-DMAC7.html)
AR (1) AR062051A1 (cg-RX-API-DMAC7.html)
AT (1) ATE485270T1 (cg-RX-API-DMAC7.html)
AU (1) AU2007276885A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0714554A2 (cg-RX-API-DMAC7.html)
CA (1) CA2659055A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002163A1 (cg-RX-API-DMAC7.html)
CO (1) CO6190511A2 (cg-RX-API-DMAC7.html)
CR (1) CR10577A (cg-RX-API-DMAC7.html)
DE (1) DE602007010010D1 (cg-RX-API-DMAC7.html)
DK (1) DK2066628T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP099087A (cg-RX-API-DMAC7.html)
GT (1) GT200900016A (cg-RX-API-DMAC7.html)
IL (1) IL196587A0 (cg-RX-API-DMAC7.html)
MA (1) MA30643B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009000830A (cg-RX-API-DMAC7.html)
NO (1) NO20090862L (cg-RX-API-DMAC7.html)
PE (1) PE20080549A1 (cg-RX-API-DMAC7.html)
PT (1) PT2066628E (cg-RX-API-DMAC7.html)
TN (1) TNSN08515A1 (cg-RX-API-DMAC7.html)
TW (1) TW200821286A (cg-RX-API-DMAC7.html)
WO (1) WO2008014186A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009072576A1 (ja) * 2007-12-04 2011-04-28 サッポロビール株式会社 骨形成促進剤
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
JP2021523135A (ja) * 2018-05-09 2021-09-02 グルソックス・バイオテック・アーベー 選択的なNox阻害活性を有する新規のスルホンアミド誘導体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52809B (sr) * 2008-11-17 2013-10-31 F. Hoffmann-La Roche Ag. Naftilsirćetne kiseline
MX2012010820A (es) 2010-03-22 2012-10-10 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
WO2012140612A1 (en) 2011-04-14 2012-10-18 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2912458B1 (en) 2012-10-24 2018-07-18 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
PH12016501764B1 (en) 2014-03-17 2024-05-17 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2017046125A1 (en) 2015-09-15 2017-03-23 Actelion Pharmaceuticals Ltd Crystalline forms
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
EP3759090A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
WO2019166632A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2021113710A1 (en) 2019-12-04 2021-06-10 Progenity, Inc. Assessment of preeclampsia using assays for free and dissociated placental growth factor
CN111333516B (zh) * 2020-04-14 2022-09-06 国药集团化学试剂有限公司 一种2-氯-5-溴硝基苯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009072576A1 (ja) * 2007-12-04 2011-04-28 サッポロビール株式会社 骨形成促進剤
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
JP2021523135A (ja) * 2018-05-09 2021-09-02 グルソックス・バイオテック・アーベー 選択的なNox阻害活性を有する新規のスルホンアミド誘導体
JP7455762B2 (ja) 2018-05-09 2024-03-26 グルソックス・バイオテック・アーベー 選択的なNox阻害活性を有する新規のスルホンアミド誘導体

Also Published As

Publication number Publication date
PE20080549A1 (es) 2008-06-20
ECSP099087A (es) 2009-02-27
CR10577A (es) 2009-03-20
WO2008014186A1 (en) 2008-01-31
PT2066628E (pt) 2010-12-31
TNSN08515A1 (en) 2010-04-14
DE602007010010D1 (de) 2010-12-02
CL2007002163A1 (es) 2008-02-08
EP2066628B1 (en) 2010-10-20
BRPI0714554A2 (pt) 2013-05-07
KR20090039735A (ko) 2009-04-22
IL196587A0 (en) 2009-11-18
MA30643B1 (fr) 2009-08-03
CA2659055A1 (en) 2008-01-31
ATE485270T1 (de) 2010-11-15
TW200821286A (en) 2008-05-16
EP2066628A1 (en) 2009-06-10
MX2009000830A (es) 2009-02-03
AU2007276885A1 (en) 2008-01-31
DK2066628T3 (da) 2011-02-07
CO6190511A2 (es) 2010-08-19
US20090176804A1 (en) 2009-07-09
GT200900016A (es) 2010-10-13
NO20090862L (no) 2009-02-24
AR062051A1 (es) 2008-08-10

Similar Documents

Publication Publication Date Title
EP2066628B1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
JP2009533473A (ja) プロスタグランジンd2受容体アンタゴニストとしての2,6−置換−4−モノ置換アミノ−ピリミジン
US20070265278A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
RU2493149C2 (ru) Замещенные метилфенилкетоны, пригодные для использования в качестве ингибиторов pde4
BRPI0712301A2 (pt) composto, composição farmacêutica, método de antagonização de um receptor dp-2, e, uso de um composto
US20110172263A1 (en) Indole derivatives as crth2 receptor antagonists
BRPI0712332A2 (pt) composto e derivados farmaceuticamente aceitáveis dos mesmos, composição farmacêutica, método de antagonização de um receptor dp-2, e, uso de um composto
AU2013259904A1 (en) Bicyclic sulfone compounds for inhibition of RORy activity and the treatment of disease
CN105209438B (zh) 苯氧基乙基二氢‑1h‑异喹啉化合物
MXPA05006701A (es) Moduladores de asma y de inflacion alergica.
ES2409833T3 (es) Sal de dihidrógeno-fosfato de un antagonista del receptor D2 de prostaglandina.
WO2018222917A1 (en) Ire1 small molecule inhibitors
TW201443004A (zh) 苯氧基乙氧基化合物
CA2601979A1 (en) 2,3 substituted pyrazine sulfonamides
ES2352725T3 (es) 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
US20130172350A1 (en) Pyrimidine compounds and their uses
MX2012010038A (es) Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2.
CN101448789A (zh) 可溶性腺苷酸环化酶抑制剂
HK1110869A (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
HK1131975B (en) 2,6-substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100712

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20111129